The company can now begin the enrollment process for its PROACTIVE-HF 2 clinical trial, which will focus on treating patients with NYHA class II heart failure. 

The new radiotracer flurpiridaz is poised to make a major impact on nuclear cardiology. Timothy Bateman, MD, co-director of the cardiovascular radiologic imaging program at Saint Luke's Mid America Heart Institute, shared details on the tracer in a new interview. 

“Our organizations are strongly opposed to this newest guidance, which further broadens the already significant discretion health plans had," RBMA and others wrote Oct. 9. 

The subcutaneous administration of CBD could make a significant impact on patient outcomes, according to new findings presented at the Heart Failure Society of America's annual meeting in Cleveland.

The newest additions cover conditions such as invasive breast cancer, sepsis, and abdominal aortic aneurysm, ACR announced Tuesday. 

Researchers explored data from the first 10 patients treated with a new self-expanding TAVR device from KOKA Lifesciences. After 30 days, there were no patient deaths and only one adverse event.

Baptist Health in Jacksonville, Florida, consolidated patient medication history from numerous facilities into one location in its Epic EHR to improve patient safety and allow data analytics.

The American College of Cardiology, Society for Cardiovascular Angiography and Interventions and Society of Thoracic Surgeons raised the issue, which is related to the billing of transcatheter heart procedures such as TAVR.